Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies

Molecular Pharmaceutics

Volumn 11, Issue 2, 2014, Pages 436-444

  Hsiao, Peng ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

blood brain barrier; cyclosporine A; drug interaction; fractional contribution of transporters; in vitro to in vivo correlation; nelfinavir; P glycoprotein; positron emission tomography; rat model prediction to human clinical

Indexed keywords

CYCLOSPORIN A; ISOFLURANE; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; VERAPAMIL; CYCLOSPORIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG INTERACTION; GENERAL ANESTHESIA; HUMAN; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RAT; SIMULATION; STEADY STATE; ANIMAL; BLOOD; CELL CULTURE; CHEMISTRY; METABOLISM; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELLS, CULTURED; CYCLOSPORINE; HUMANS; MALE; NELFINAVIR; P-GLYCOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 84893312014     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400396k     Document Type: Article

References (42)

1. Schinkel, A. H.; Wagenaar, E.; Mol, C. A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs J. Clin. Invest. 1996, 97, 2517-24 (Pubitemid 26187339)
2. Hendrikse, N. H.; Schinkel, A. H.; de Vries, E. G.; Fluks, E.; Van der Graaf, W. T.; Willemsen, A. T.; Vaalburg, W.; Franssen, E. J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography Br. J. Pharmacol. 1998, 124, 1413-8 (Pubitemid 28360563)
3. Kim, R. B.; Fromm, M. F.; Wandel, C.; Leake, B.; Wood, A. J.; Roden, D. M.; Wilkinson, G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors J. Clin. Invest. 1998, 101, 289-94 (Pubitemid 28067324)
4. Choo, E. F.; Kurnik, D.; Muszkat, M.; Ohkubo, T.; Shay, S. D.; Higginbotham, J. N.; Glaeser, H.; Kim, R. B.; Wood, A. J.; Wilkinson, G. R. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier J. Pharmacol. Exp. Ther. 2006, 317, 1012-8 (Pubitemid 43764103)
5. Choo, E. F.; Leake, B.; Wandel, C.; Imamura, H.; Wood, A. J.; Wilkinson, G. R.; Kim, R. B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes Drug Metab. Dispos. 2000, 28, 655-60 (Pubitemid 30390404)
6. Sasongko, L.; Link, J. M.; Muzi, M.; Mankoff, D. A.; Yang, X.; Collier, A. C.; Shoner, S. C.; Unadkat, J. D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography Clin. Pharmacol. Ther. 2005, 77, 503-14 (Pubitemid 40824964)
7. Eyal, S.; Ke, B.; Muzi, M.; Link, J. M.; Mankoff, D. A.; Collier, A. C.; Unadkat, J. D. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography Clin. Pharmacol. Ther. 2010, 87, 579-85
8. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-22
9. Martin, C.; Berridge, G.; Higgins, C. F.; Mistry, P.; Charlton, P.; Callaghan, R. Communication between multiple drug binding sites on P-glycoprotein Mol. Pharmacol. 2000, 58, 624-32
10. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein Br. J. Pharmacol. 1999, 128, 403-11 (Pubitemid 29458600)
11. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis Biochemistry 2000, 39, 11901-6
12. Shapiro, A. B.; Fox, K.; Lam, P.; Ling, V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site Eur. J. Biochem. 1999, 259, 841-50 (Pubitemid 29075514)
13. Taub, M. E.; Podila, L.; Ely, D.; Almeida, I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity Drug Metab. Dispos. 2005, 33, 1679-87 (Pubitemid 41539967)
14. Kaddoumi, A.; Choi, S. U.; Kinman, L.; Whittington, D.; Tsai, C. C.; Ho, R. J.; Anderson, B. D.; Unadkat, J. D. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid Drug Metab. Dispos. 2007, 35, 1459-62 (Pubitemid 47296072)
15. Hsiao, P.; Bui, T.; Ho, R. J.; Unadkat, J. D. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier Drug Metab. Dispos. 2008, 36, 481-4 (Pubitemid 351397990)
16. Hsiao, P.; Sasongko, L.; Link, J. M.; Mankoff, D. A.; Muzi, M.; Collier, A. C.; Unadkat, J. D. Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data J. Pharmacol. Exp. Ther. 2006, 317, 704-10
17. Passchier, J.; Comley, R.; Salinas, C.; Rabiner, E.; Gunn, R.; Cunningham, V.; Wilson, A.; Houle, S.; Gee, A.; Laruelle, M. Blood brain barrier permeability of [11C]loperamide in humans under normal and impaired P-glycoprotein function J. Nucl. Med. 2008, 49, 211P
18. Hsiao, P.; Unadkat, J. D. P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans Mol. Pharmaceutics 2012, 9, 629-33
19. Shibata, N.; Gao, W.; Okamoto, H.; Kishida, T.; Yoshikawa, Y.; Takada, K. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats J Pharm Pharmacol 2002, 54, 221-9 (Pubitemid 34150059)
20. Anderson, B. D.; May, M. J.; Jordan, S.; Song, L.; Roberts, M. J.; Leggas, M. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats Drug Metab. Dispos. 2006, 34, 653-9
21. Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir Antimicrob. Agents Chemother. 1997, 41, 654-60 (Pubitemid 27098420)
22. Zhang, K. E.; Wu, E.; Patick, A. K.; Kerr, B.; Zorbas, M.; Lankford, A.; Kobayashi, T.; Maeda, Y.; Shetty, B.; Webber, S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities Antimicrob. Agents Chemother. 2001, 45, 1086-93 (Pubitemid 32230986)
23. Shetty, B. V.; Kosa, M. B.; Khalil, D. A.; Webber, S. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease Antimicrob. Agents Chemother. 1996, 40, 110-4 (Pubitemid 26020750)
24. Sugioka, N.; Sato, K.; Haraya, K.; Maeda, Y.; Yasuda, K.; Fukushima, K.; Ito, Y.; Takada, K. Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats Biopharm. Drug Dispos. 2008, 29, 469-79
25. Boxenbaum, H. Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition J. Pharm. Pharm. Sci. 1999, 2, 89-91
26. Ito, K.; Hallifax, D.; Obach, R. S.; Houston, J. B. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm Drug Metab. Dispos. 2005, 33, 837-44 (Pubitemid 40686638)
27. Rowland, M.; Matin, S. B. Kinetics of drug-drug interactins J. Pharmacokinet. Biopharm. 1973, 1, 553-567
28. Zamek-Gliszczynski, M. J.; Kalvass, J. C.; Pollack, G. M.; Brouwer, K. L. Relationship between drug/metabolite exposure and impairment of excretory transport function Drug Metab. Dispos. 2009, 37, 386-90
29. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios Drug Metab. Dispos. 2007, 35, 660-6 (Pubitemid 46513270)
30. Manitpisitkul, P.; Chiou, W. L. Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans Biopharm. Drug Dispos. 1993, 14, 555-66 (Pubitemid 23303541)
31. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 2011, 117, 333-45
32. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576 Cancer Res. 2001, 61, 749-58 (Pubitemid 32128642)
33. Lazarova, N.; Zoghbi, S. S.; Hong, J.; Seneca, N.; Tuan, E.; Gladding, R. L.; Liow, J. S.; Taku, A.; Innis, R. B.; Pike, V. W. Synthesis and evaluation of [ N -methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function J. Med. Chem. 2008, 51, 6034-43
34. Kreisl, W. C.; Liow, J. S.; Kimura, N.; Seneca, N.; Zoghbi, S. S.; Morse, C. L.; Herscovitch, P.; Pike, V. W.; Innis, R. B. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide J. Nucl. Med. 2010, 51, 559-66
35. 11C-loperamide and its N -desmethyl radiometabolite are avid substrates for brain permeability- glycoprotein efflux J. Nucl. Med. 2008, 49, 649-56 (Pubitemid 351520614)
36. Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrik, M.; Fankhanel, M.; Spruss, T.; Bernhardt, G.; Graeff, C.; Farber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo J. Clin. Invest. 2002, 110, 1309-18 (Pubitemid 35285757)
37. Gupta, A.; Zhang, Y.; Unadkat, J. D.; Mao, Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2) J. Pharmacol. Exp. Ther. 2004, 310, 334-41 (Pubitemid 38812728)
38. Corkill, G.; Turner, D.; Pufong, B.; Gill, H.; Fessey, R.; Dilworth, C. In vitro evaluation of P-glycoprotein inhibition using loperamide as a probe substrate. In 10th European ISSX Meeting, 2008.
39. Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.; Feng, B.; Huang, S. M.; Liu, X.; Smith, Q. R.; Zhang, L. K.; Zamek-Gliszczynski, M. J. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: The ITC evidence-based position Clin. Pharmacol. Ther. 2013, 94, 80-94
40. Polli, J. W.; Baughman, T. M.; Humphreys, J. E.; Jordan, K. H.; Mote, A. L.; Salisbury, J. A.; Tippin, T. K.; Serabjit-Singh, C. J. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine J. Pharm. Sci. 2003, 92, 2082-9 (Pubitemid 37175638)
41. Kemper, E. M.; Verheij, M.; Boogerd, W.; Beijnen, J. H.; van Tellingen, O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein Eur. J. Cancer 2004, 40, 1269-74 (Pubitemid 38526348)
42. El Ela, A. A.; Hartter, S.; Schmitt, U.; Hiemke, C.; Spahn-Langguth, H.; Langguth, P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds: Implications for pharmacokinetics of selected substrates J. Pharm. Pharmacol. 2004, 56, 967-75